alexa Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay.
General Science

General Science

Journal of Bioterrorism & Biodefense

Author(s): Porter A, Phillips G, Smith L, ErwinCohen R, Tammariello R,

Abstract Share this page

Abstract To protect against ricin intoxication, a genetically derived ricin A chain vaccine candidate (RVEc) was developed lacking the toxic N-glycosidase activity (Olson et al., 2004). The vaccine protects animals against an aerosolized ricin holotoxin (RT) challenge (Carra et al., 2007). In the current study, the RVEc vaccine was evaluated for its interaction and effect on human endothelial cells. RVEc was tested in an in vitro cellular-based bioassay, consisting of primary human endothelial cells cultured on collagen-coated inserts, to which concentrations of the vaccine candidate (0.6, 2, 2.5 or 9 μM) were added. RVEc showed no signs of adverse activity on the cells (e.g., cytotoxicty activity) as measured by changes in trans-endothelial electrical resistance (TEER). In contrast, ricin toxin (RT) cytotoxicity was observed at all concentrations tested. Under light microscopy, no cytotoxicity was visible at 24h with 0.6 or 9 μM of RVEc. However, cytotoxicity was observed for RT and to a lesser degree for RTA. Flow cytometric analysis showed binding of RT, slight binding of RTA, and no binding of the RVEc vaccine to endothelial cells. The presence of RTB as a contaminant contributing to the cytotoxicity in the RTA preparation was ruled out by a RTB-specific ELISA. In addition, RTA at 9 μM produced a cytotoxic activity that could not be explained exclusively by the presence of azide in the RTA buffer. In the current study, the model demonstrated no discernable adverse events of the RVEc vaccine on human endothelial cells, when compared to the toxicity caused by holotoxin or native RTA preparations. Published by Elsevier Ltd. This article was published in Toxicon and referenced in Journal of Bioterrorism & Biodefense

Relevant Expert PPTs

Relevant Speaker PPTs

  • Eugene Stephane Mananga
    On Fer and Floquet-Magnus expansions: Application in solid-state nuclear magnetic resonance and physics
    PDF Version
  • Ekambaram Umapathy
    An association between vasoactive agents and etiology of hypertension and obesity in HIV patients in Mthatha, South Africa
    PPT Version | PDF Version
  • K Mulkijanyan
    Plant biopolymers from Boraginaceae family species and their synthetic derivatives: Prospective pharmacological agents
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Seema Bhargava
    Should therapeutic agents for sepsis target the glycocalyx?
    PPT Version | PDF Version
  • Thorsten Zehlicke
    Acute sinusitis - Treatment and management with mucolytic agents
    PPT Version | PDF Version
  • C. Diaz
    New Antibacterial Agents against Gram-negative Pathogens from a Fundacion MEDINA’s Microbial Natural Products Collection Screening
    PPT Version | PDF Version
  • De-chu Christopher Tang
    Activation of protective innate-adaptive immunity duo for conferring rapid-sustained-broad protection of vaccines against infectious agents
    PPT Version | PDF Version
  • Shuba Dharmana
    Review of topical lightening agents
    PPT Version | PDF Version
  • Lucia Gemma Delogu
    Functionalized carbon nanotubes as immunomodulator systems and ultrasound contrast agents
    PPT Version | PDF Version
  • Viral Kansara
    Ocular melanin modulates pharmacokinetics and drug disposition of therapeutic agents
    PPT Version | PDF Version
  • Elena Gavrilova
    Application of drugs based on release-active antibodies as immunotherapy agents
    PPT Version | PDF Version
  • Philip J. Lucas
    Differential gene expression in the thymus to establish low toxicity chemotherapeutic agents
    PPT Version | PDF Version
  • Emad. A. Mowafy
    Design and Development of novel reagents for rapid and selective extraction and separation of selected precious metals
    PPT Version | PDF Version
  • Aina Westrheim Ravna
    Novel sildenafil analogues: possible drugs for increased sensitivity to chemotherapeutic agents
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version